CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder
Open Access
- 18 January 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (1) , e30341
Abstract
A major challenge for the treatment of many central nervous system (CNS) disorders is the lack of convenient and effective methods for delivering biological agents to the brain. Mucopolysaccharidosis II (Hunter syndrome) is a rare inherited lysosomal storage disorder resulting from a deficiency of iduronate-2-sulfatase (I2S). I2S is a large, highly glycosylated enzyme. Intravenous administration is not likely to be an effective therapy for disease-related neurological outcomes that require enzyme access to the brain cells, in particular neurons and oligodendrocytes. We demonstrate that intracerebroventricular and lumbar intrathecal administration of recombinant I2S in dogs and nonhuman primates resulted in widespread enzyme distribution in the brain parenchyma, including remarkable deposition in the lysosomes of both neurons and oligodendrocytes. Lumbar intrathecal administration also resulted in enzyme delivery to the spinal cord, whereas little enzyme was detected there after intraventricular administration. Mucopolysaccharidosis II model is available in mice. Lumbar administration of recombinant I2S to enzyme deficient animals reduced the storage of glycosaminoglycans in both superficial and deep brain tissues, with concurrent morphological improvements. The observed patterns of enzyme transport from cerebrospinal fluid to the CNS tissues and the resultant biological activity (a) warrant further investigation of intrathecal delivery of I2S via lumbar catheter as an experimental treatment for the neurological symptoms of Hunter syndrome and (b) may have broader implications for CNS treatment with biopharmaceuticals.Keywords
This publication has 60 references indexed in Scilit:
- Safety Evaluation of Chronic Intrathecal Administration of Idursulfase-IT in Cynomolgus MonkeysToxicologic Pathology, 2011
- Structure and function of the blood–brain barrierNeurobiology of Disease, 2010
- Pharmacokinetics and Brain Uptake of a Genetically Engineered Bifunctional Fusion Antibody Targeting the Mouse Transferrin ReceptorMolecular Pharmaceutics, 2009
- Genetic engineering of IgG-glucuronidase fusion proteinsJournal of Drug Targeting, 2009
- AGT-181: Expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeysJournal of Biotechnology, 2009
- Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood–brain barrier delivery in the mouseBiotechnology and Bioengineering, 2008
- Intrathecal drug therapy for long-term pain managementAmerican Journal of Health-System Pharmacy, 2007
- The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome)Journal of Inherited Metabolic Disease, 2007
- Distinct Genomic Integration of MLV and SIV Vectors in Primate Hematopoietic Stem and Progenitor CellsPLOS Biology, 2004
- Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS IMolecular Genetics and Metabolism, 2004